Structure-based design of antiviral drug candidates targets SARS-CoV-2 main protease

(Chinese Academy of Sciences Headquarters) A team of Chinese scientists has recently developed two novel compounds that inhibit the SARS-CoV-2 main protease (Mpro) and one of them is a good drug candidate for further clinical studies. The research, published online inScience on April 22, was conducted by the researchers from the Shanghai Institute of Materia Medica of the Chinese Academy of Sciences (CAS), ShanghaiTech University, the Wuhan Institute of Virology of CAS, and their collaborators.
Source: EurekAlert! - Infectious and Emerging Diseases - Category: Infectious Diseases Source Type: news